Patents by Inventor Carole GUILLONNEAU

Carole GUILLONNEAU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10105425
    Abstract: The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to an isolated peptide of 15 or 16 amino acids long that comprises or consists of the amino acid sequence: REEYARFDSDVGEYR (SEQ ID NO: 1) or a function-conservative variant for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 23, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes
    Inventors: Carole Guillonneau, Ignacio Anegon, Elodie Picarda
  • Publication number: 20180251731
    Abstract: Disclosed is a new subpopulation of CD8+CD45RClow Tregs, namely IFN?+IL-10+IL-34+ secreting population of CD8+CD45RClow Treg cells, methods for their isolation and expansion and their use as drug, more particularly for immunotherapy as well as biomarker
    Type: Application
    Filed: September 6, 2016
    Publication date: September 6, 2018
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Séverine BEZIE
  • Publication number: 20180187151
    Abstract: Disclosed is a method for obtaining a population of human Treg cells including the steps of: (a) culturing a population of human monocytes with a medium including an amount of an interleukin-34 (IL-34) polypeptide in order to obtain a population of immunosuppressive macrophages; (b) co-culturing a population of human peripheral blood mononuclear cells (PBMCs) and the population of immunosuppressive macrophages obtained at step (a).
    Type: Application
    Filed: July 1, 2016
    Publication date: July 5, 2018
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Severine BEZIE
  • Publication number: 20180106779
    Abstract: Disclosed is a method for labeling, detecting and/or isolating Foxp3+ Treg cells from a biological sample containing peripheral blood mononuclear cells (PBMC) or lymphocytes including the following steps of: (i) coupling the surface of PBMC or lymphocytes to a capture moiety which binds to the cell through a cell surface molecule and to interleukin-34 (IL34), (ii) culturing the lymphocytes under conditions wherein IL34 is secreted, released and specifically captured by the capture moiety, (iii) labeling the IL34 expressing lymphocytes with a label moiety, and (iv) optionally detecting and/or isolating the IL34 expressing lymphocytes which are Foxp3+ Treg cells. Also disclosed is an isolated population of Foxp3+ Treg cells obtainable by the method and uses thereof.
    Type: Application
    Filed: May 12, 2016
    Publication date: April 19, 2018
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Severine BEZIE
  • Publication number: 20170226209
    Abstract: The invention relates to an isolated anti-CD45RC antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with CD45RC+ cells. The invention relates to an isolated anti-CD45RC antibody for use in expanding and/or potentiating regulatory T cells.
    Type: Application
    Filed: July 31, 2015
    Publication date: August 10, 2017
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON
  • Publication number: 20170202921
    Abstract: The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
    Type: Application
    Filed: July 17, 2015
    Publication date: July 20, 2017
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Sandrine BEZIE
  • Publication number: 20170173125
    Abstract: The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to isolated peptide of length ranging between 11 and 16 amino acids comprising the amino acid sequence: SDVGEYR (SEQ ID NO: 1) or a function-conservative variant thereof for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
    Type: Application
    Filed: April 1, 2015
    Publication date: June 22, 2017
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ DE NANTES
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Elodie PICARDA
  • Publication number: 20170021001
    Abstract: The invention relates to an peptide derived from a polymorphic region of donor MHC class II molecules which induces tolerance and thus prevents transplant rejection in a patient in need thereof. The invention relates to an isolated peptide of 15 or 16 amino acids long that comprises or consists of the amino acid sequence: REEYARFDSDVGEYR (SEQ ID NO: 1) or a function-conservative variant for use as drug. The invention relates to an in vitro method for determining whether a transplanted patient is tolerant, comprising a step of determining the presence of CD8+CD45RClow Tregs in a biological sample obtained from said transplanted patient, wherein the presence of CD8+CD45RClow Tregs is indicative of tolerance.
    Type: Application
    Filed: April 1, 2015
    Publication date: January 26, 2017
    Inventors: Carole GUILLONNEAU, Ignacio ANEGON, Elodie PICARDA